EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer
Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer.
Related Articles
Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma
Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.
Frontline Ficerafusp Alfa Plus Pembrolizumab Shows Promise in HPV-Negative HNSCC
Ficerafusp alfa plus pembrolizumab elicited deep responses in HPV-negative recurrent or metastatic head and neck cancer.
Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC
Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.
Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC
Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.
Rusfertide Shines as New Treatment Option in Polycythemia Vera
In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy.
Belantamab Mafodotin Triplet Improves PFS, Responses in R/R Myeloma With High-Risk Cytogenetics
Belantamab mafodotin plus Pd improved PFS and response rates in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.
Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC
Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.
Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma
Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.
Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC
Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.
Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC
First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.